Grufity logo
Grufity logo
FNCH

FNCH - Finch Therapeutics Group, Inc. Stock Price, Fair Value and News

$7.50-0.05 (-0.66%)
Market Closed as of 11 Jun 2026, 04:00 pm ET

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FNCH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FNCH Price Action

Last 30 days

11.7%

Last 90 days

-43.8%

Trailing 12 Months

-45.3%

FNCH RSI Chart

FNCH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FNCH Valuation

Market Cap

12.0M

Price/Earnings (Trailing)

-0.84

Price/Sales (Trailing)

111.8

EV/EBITDA

0.3

Price/Free Cashflow

-0.66

FNCH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FNCH Fundamentals

FNCH Revenue

FNCH Earnings

FNCH Profitability

Free Cashflow Yield

-150.81%

FNCH Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2023614.0K253.0K115.0K107.0K
202214.1M9.7M5.3M861.0K
20219.5M10.0M19.5M18.5M
2020---7.7M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Finch Therapeutics Group, Inc.

FNCH
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
 WEBSITEfinchtherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES18

Finch Therapeutics Group, Inc. Frequently Asked Questions

FNCH is the stock ticker symbol of Finch Therapeutics Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri May 29 2026, market cap of Finch Therapeutics Group, Inc. is 11.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri May 29 2026, FNCH's PE ratio (Price to Earnings) is -0.84 and Price to Sales (PS) ratio is 111.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FNCH PE ratio will change depending on the future growth rate expectations of investors.